Content about Takeda Pharmaceuticals North America

April 5, 2011

Studies have indicated that proton-pump inhibitors, used for treating gastroesophageal reflux disease, reduce the efficacy of a popular blood-thinning drug, but Takeda Pharmaceuticals North America announced on Tuesday the results of a new study indicating that its own PPIs may have less of an effect.

NEW ORLEANS — Studies have indicated that proton-pump inhibitors, used for treating gastroesophageal reflux disease, reduce the efficacy of a popular blood-thinning drug, but Takeda Pharmaceuticals North America announced on Tuesday the results of a new study indicating that its own PPIs may have less of an effect.

December 22, 2010

Takeda and its subsidiary settled the patent suits it brought against generic drug makers that sought to develop their own versions of its diabetes treatment.

DEERFIELD, Ill., and OSAKA, Japan — Takeda and its subsidiary settled the patent suits it brought against generic drug makers that sought to develop their own versions of its diabetes treatment.

September 16, 2010

The Food and Drug Administration said Friday it had begun a safety review of Takeda’s...

SILVER SPRING, Md. The Food and Drug Administration said Friday it had begun a safety review of Takeda’s Type 2 diabetes treatment Actos (pioglitazone) after receiving five-year data from a 10-year study Takeda Pharmaceuticals North America is conducting on the drug showing that some patients taking it could be at risk for bladder cancer.